Nanyang Biologics to Go Public in $1.5 Billion Deal with <a href="https://laohu8.com/S/RFAIU">RF Acquisition Corp. II</a>
RF Acquisition Corp. II has announced it has entered into a business combination agreement with Nanyang Biologics Pte. Ltd. (NYB), a pioneer in AI-driven drug discovery. The transaction, which values NYB at approximately $1.5 billion in pre-transaction equity, is expected to result in the combined company being listed on Nasdaq under the ticker symbol "NYB." NYB's current shareholders, including The9 and Mercatus Capital, will roll over their equity and retain a majority stake in the new entity, with NYB designating a majority of the board of directors. Upon completion, NYB plans to accelerate its work in drug discovery, particularly in integrating traditional medicine with advanced technology. The transaction has been approved by the boards of both companies and is expected to close in the first or second quarter of 2026, subject to customary conditions. The announcement was made by RF Acquisition Corp. II.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RF Acquisition Corp. II published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-007836), on October 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.